Longxuetongluo, a kind of traditional Chinese medicine capsule in the treatment of meridian apoplexy (Cerebral Infarction) during the recovery period:An open, multi-center, phase IV clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-16007950

Enrollment

Unknown

Registered

2016-02-19

Start date

2016-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meridian apoplexy (Cerebral Infarction) during the recovery period

Interventions

test group:???

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meet the Western medicine diagnosis criteria of Cerebral Infarction; 2. Meet the TCM diagnosis criteria of meridian apoplexy during the recovery period; 3. Patients should be voluntary to the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. patients who have brain diseases such as progressive cerebral stroke, transient ischemic attack, cerebral infarction with cerebral hemorrhage and cerebral arteries; 2. patients who have brain diseases such as brain tumor, brain trauma, brain parasites,et al.; 3. pregnant or lactating women; 4. patients who are allergic to any known components of the test drug; 5. patients who have active ulcers and bleeding tendency.

Design outcomes

Primary

Measure	Time frame
NIHSS;the incidence of adverse events and/or adverse reactions;	—

Secondary

Measure	Time frame
mRS;Barthel index;SSQOL;Symptom classification standards;	—

Countries

China

Contacts

Public ContactBian Jinling

bjlyisheng@yahoo.com.cn+86 13502171616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026